NCT01756261View on ClinicalTrials.gov

EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan

CompletedOBSERVATIONAL
Enrollment

757

Participants

Timeline

Start Date

December 26, 2012

Primary Completion Date

July 20, 2016

Study Completion Date

February 27, 2017

Conditions
Macular Degeneration
Interventions
DRUG

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Patients treated with EYLEA under practical manner for AMD.

Trial Locations (1)

Unknown

Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Bayer

INDUSTRY

NCT01756261 - EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan | Biotech Hunter | Biotech Hunter